Potassium Channel Regulation Dysfunction Underlies Restless Legs Syndrome: A Framework Involving Membrane Potential Polarization Disorder

Authors:

Xin Yao, MD

Department of Rehabilitation, Affiliated Yueqing Hospital of Wenzhou Medical University

Corresponding author:

Xin Yao, MD

Department of Rehabilitation, Affiliated Yueqing Hospital of Wenzhou Medical University, No. 338, Qingyuan Road, Yueqing City, Zhejiang Province, China 325600.

E-mail: yaoxinhongqiao@163.com

Tel: +86-13868328538

Abstract

Restless legs syndrome (RLS) is a common neurological disorder whose pathophysiology remains poorly understood; it is currently defined only by diagnostic criteria. Opioids are used for treatment-resistant RLS, but long-term use could lead to tolerance and addiction. This study conducted linkage disequilibrium score correlation (LDSC) and bidirectional Mendelian randomization analyses on genome-wide association study (GWAS) data for opioids use (N=78808) and RLS (N=48808), and performed mediation analysis using 1402 cerebrospinal fluid and brain metabolites as potential mediators to identified and evaluate four mediators. A simulated temporal mediation model based on the four mediators provided potential genetic evidence for the underlying mechanism of the dynamic causal relationship between opioids use and RLS. Reverse MR analysis result showed that RLS is a risk factor for opioids use, suggesting that patients with genetically driven RLS are more prone to opioid dependence. Enrichment analysis of genes mapped from instrumental variable linked to RLS-retaled metabolites shows, the mechanism of RLS mainly involves potassium channel regulation, synaptic function and addiction. Further inference based on existing studies supports the hypothesis that RLS involves disrupted membrane potential polarization, potentially driven by potassium channel regulation dysfunction.

Keywords: Restless legs syndrome; Opioids; Mendelian randomization; Membrane potential polarization disorder; Potassium ion channels; Cerebrospinal fluid and brain metabolites; Simulated temporal mediation model; Pathophysiology

1 Introduction

Restless legs syndrome (RLS) affects approximately 7.12% of the global population (95% CI = 5.15–9.76), equating to 356.07 million affected individuals worldwide, and represents one of the most common neurological disorders[1]. Despite extensive research, its pathophysiology remains poorly understood; RLS is currently defined only by clinical diagnostic criteria. Existing hypotheses focus on brain iron deficiency and dopamine dysregulation, but neither fully explains RLS[2]. For example, cerebrospinal fluid (CSF) levels of 3-Ortho-methyldopa (a dopamine metabolite) are elevated in RLS patients and positively correlated with disease severity, suggesting dopamine synthesis hyperactivity[3]. Additionally, imaging studies and autopsy findings indicate concurrent secondary dopamine receptor downregulation[4]. These observations contradict simple dopamine-deficiency models.

Notably, CSF and autopsy studies in RLS patients have found a deficiency of endogenous opioid[5,6]. Consistent with this, mice with knockout opioid receptors exhibit RLS-like symptoms[7]. Clinically, opioids have proven effective: a double-blind, randomised trial showed that controlled-release oxycodone–naloxone produced significant and sustained improvement in severe RLS[8], and long-term follow-ups reported maintained efficacy without notable tolerance[9,10]. Nonetheless, opioids use is limited due to tolerance and addiction issues. The pathogenesis of RLS and the dynamic evolution mechanism of opioids use are unclear, that makes it difficult to carry out effective stratified and individualized treatment, which may further increase concerns about long-term opioids use.

Recent advances in Mendelian randomization (MR) methodology and large-scale GWAS data enable investigation of causal relationships between exposures and outcomes[11]. Moreover, CSF and brain metabolites directly reflect brain biochemical states, making them valuable mediators for understanding complex neurological disorders. In this study, a simulated temporal mediation MR framework was employed to investigate the dynamic relationship between opioids use and RLS, incorporating

mediation analysis with 1,402 CSF and brain metabolites to further explored the mechanisms underlying RLS. The findings, combined with existing study evidence, led to the proposal of a novel pathophysiological framework—"Multi-system Membrane Potential Polarization disorder" hypothesis—which suggests that membrane potential abnormalities act as a central link between diverse upstream etiologies and downstream similar mechanisms/symptoms, that provided a potential unified explanation for RLS manifestations, comorbidity patterns, iron metabolism disorders, dopaminergic system change, and therapeutic responses.

2　Methods

2.1　Study Design and Data Sources

A two-sample bidirectional MR study was conducted using summary statistics from large-scale GWAS, aligning all data to the GRCh38 genome build. Data sources included:

- **Opioids Use GWAS:** Summary dataset for self-reported prescription opioids use (22,982 cases and 55,826 controls; N = 78,808) from a UK Biobank study[12].

- **RLS GWAS dataset 1:** Meta-analysis of European-ancestry GWAS (9,851 cases and 38,957 controls; N = 48,808) was obtained from the GWAS Catalog (GCST90435387), and derived from a large-scale genome-wide association meta-analysis[13].

- **RLS GWAS dataset 2:** The second RLS GWAS (7,248 cases and 19,802 controls; N = 27,050) was obtained from the GWAS Catalog (GCST90399568), and derived from the EU-RLS-GENE consortium genome-wide association study[14].

- **CSF and brain metabolite GWAS:** Summary datasets for 440 CSF metabolites and 962 brain tissue metabolites were obtained from the study by Cruchaga et al[15]. (CSF, n = 2602; brain tissue, n = 1,016).

- **GSE271674 dataset from Gene Expression Omnibus (GEO) database:** To

provide experimental validation of the potassium channel regulation dysfunction, RNA-seq dataset from GEO (GSE271674). This dataset investigated MEIS1 transcription factor function in human neural stem cells[16], comprising 36 samples across six experimental conditions: MEIS1 overexpression (CRISPRa_MEIS1), MEIS1 knockout (CRISPR-KO_MEIS1), and their respective controls, with 6 biological replicates per condition (N=36). MEIS1 harbors the strongest genetic risk factor for RLS and represents a key regulatory node in RLS pathophysiology, making this dataset particularly relevant for validating our findings regarding potassium channel gene regulation in RLS.

- **Potassium channel gene eQTLs:** eQTL data for 50 potassium channel-related genes datasets was obtained from the OpenGWAS website (https://gwas.mrcieu.ac.uk) for cis-Mendelian randomization (cis-MR)[17].

Fig. 1 Overall study design

2.2 Genetic Instrument Selection

Instrument Variable Quality Control Standards: Stringent quality control criteria were implemented for all genetic instruments:

- Significance thresholds: $P<5\times10^{-8}$ for opioids use, RLS1, RLS2 and OpenGWAS eQTL datasets; $P<1\times10^{-5}$ for CSF and brain metabolite datasets due to smaller sample sizes

- Minor allele frequency (MAF): >0.01 to ensure adequate statistical power

- F-statistics: >10 to ensure strong instrument strength, calculated using an improved formula: $R^2 = [2\times\beta^2\times EAF\times(1-EAF)] / [2\times\beta^2\times EAF\times(1-EAF) + 2\times SE^2\times N\times EAF\times(1-EAF)]$, then $F = [R^2\times(N-k-1)] / [(1-R^2)\times k]$, where β is the effect size, SE is the standard error, EAF is the effect allele frequency, N is the sample size, and k=1 for single SNP evaluation

- Linkage disequilibrium (LD) clumping: $r^2<0.001$, window=10,000kb using European reference panels (GRCh38) for opioids use, RLS1, RLS2 and CSF and brain metabolite datasets; $r^2<0.3$, window=100kb using European reference panels (GRCh38) for genetic region within 100 kb pairs on either side of the target genes from OpenGWAS eQTL datasets

- Palindromic SNP handling: Removal of A/T and G/C SNPs with ambiguous strand orientation and eaf close to 0.5 (0.45-0.55).

For opioids use, one SNP (rs2618039) reached genome-wide significance, mapping to the KCND3 gene and encoding a voltage-gated potassium channel (F-statistics=30.6).

For RLS dataset 1, seven independent genetic variants reaching genome-wide significance were selected, after excluding rs7779977 due to outlier behavior and mapping to pseudogenes. All F-statistics for RLS instruments>10.

For CSF and brain metabolites, a relaxed threshold ($P<1\times10^{-5}$) yielded sufficient instruments for each metabolite (all F>10). Additional filtering removed SNPs associated with 280 potential confounders.

For potassium channel gene eQTLs, 40 cis-eQTL instrument data were extracted from 50 OpenGWAS eQTL datasets for cis-MR.

2.3   Statistical Analyses

Linkage Disequilibrium Score Correlation (LDSC)[18]: LDSC was used to evaluate the genetic correlation between opioids use, RLS dataset 1 and RLS dataset 2.

Mendelian Randomization: Two-sample bidirectional MR was performed using inverse variance weighted (IVW) method as primary analysis (Wald ratio method for single instrumental variable), supplemented by MR-Egger regression, weighted median method, and MR-PRESSO for pleiotropy detection and outlier correction[19]. Comprehensive sensitivity analyses included Cochran's Q statistic for heterogeneity testing[20], MR-Egger intercept test for horizontal pleiotropy detection[21], and leave-one-out analysis for influential variant identification.

Mediation Analysis: The analysis employed a two-stage approach: Stage 1 estimated effects of opioid use on each metabolite. Stage 2 estimated effects of each metabolite on RLS risk. The indirect effect for each mediator was calculated as the product of Stage 1 and Stage 2 effects, and mediation proportion was defined as (indirect effect / total effect) × 100%. Negative mediation proportions indicate masking effects, where risk pathways counteract the direct protective effect of opioids, thereby explaining attenuated overall causality.

Simulated temporal Mediation Model: This model aims to explore the underlying mechanism by mimicking the dynamic relationship between opioids use and RLS. This model incorporates the following key assumptions and components:

Model Assumptions:

1. Temporal heterogeneity: Opioid effects on RLS vary across different time periods

2. Multiple pathways: The protective and risk-promoting pathways may play a role at different stages.

3. Masking effects: Long-term risk-promoting mediators counteract and mask the constant direct protective effects mediated through potassium channel activation

Model Components:

1. Direct effect (τ): Constant protective effect through potassium channel activation (KCND3 gene), independent of time

2. Short-term mediation: Protective effects via:

- Hypothalamic-Pituitary-Adrenal (HPA) axis suppression (reduced cortisol)

- Blood-brain barrier modulation (reduced urea)

- Immediate neuroprotective mechanisms

3. Long-term mediation: Risk effects via:

- Metabolic dysregulation (reduced fructose affecting dopamine reward)

- Tolerance development (ceramide accumulation)

- Neuroadaptive changes

4. Net effect calculation: Total effect = Direct effect + Short-term mediation - Long-term mediation

Mathematical Framework:

Total Effect = τ + Σ(a-short-term × b-short-term) - Σ(a-long-term × b-long-term)

Where a represents exposure-mediator effects and b represents mediator-outcome effects.

Genetic Colocalization Analysis: To identify shared causal variants between CSF/brain metabolites and RLS dataset 1, Bayesian genetic colocalization analysis[22] was performed using the coloc R package. For each significant CSF/brain metabolite identified in the mediation analysis, genomic regions of ±500kb around each instrumental variable SNP were defined. Within these regions, overlapping SNPs from both the metabolite GWAS and RLS GWAS datasets were extracted, requiring a minimum of 10 shared SNPs for analysis. The colocalization analysis calculated five posterior probabilities: PP.H0 (no association), PP.H1 (association with metabolite only), PP.H2 (association with RLS only), PP.H3 (independent associations), and PP.H4 (shared causal variant). PP.H4 > 0.75 was considered as strong evidence for genetic colocalization, indicating that the same causal variant influences both the metabolite level and RLS risk. This analysis helps distinguish between true shared genetic architecture and spurious associations due to linkage disequilibrium.

Enrichment Analysis Gene Selection: For functional enrichment analysis, genes were extracted from genomic regions surrounding significant instrumental variables identified in the mediation analysis. Specifically, genes were derived from ±50kb

flanking regions of SNPs serving as instrumental variables for CSF and brain metabolites that showed significant associations (IVW P<0.05) with RLS in the Mendelian randomization analysis. This approach ensures that the enrichment analysis captures genes potentially influenced by the same regulatory mechanisms underlying the metabolite-RLS associations, providing biological context for the observed causal relationships.

A systematic four-step gene filtering strategy was implemented to ensure high-quality gene selection: (1) Duplicate removal: redundant gene entries were eliminated to avoid bias in enrichment analysis; (2) Functional annotation filtering: genes were queried through the GeneCards database (https://www.genecards.org/) to filter genes based on comprehensive functional annotations and disease relevance; (3) SNP-gene correspondence optimization: genes were prioritized to achieve one-to-one correspondence with SNPs where possible, reducing mapping ambiguity; (4) Protein-coding gene restriction: only protein-coding genes were retained to focus on functionally relevant targets with direct therapeutic implications. Through this rigorous filtering process, the final gene set was refined from an initial 2,879 SNP-mapped genes to 486 unique high-quality genes. Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analyses were performed to identify significantly enriched biological processes, cellular components, molecular functions, and metabolic pathways (p.adjust<0.05).

2.4 Validation Analyses

Validation Analysis 1: To validate these findings, a replication analysis for the key steps was conducted using the RLS GWAS dataset 2. The MR analysis was conducted using the same 1402 CSF and brain metabolites as exposures with the RLS dataset 2 as an outcome. The functional enrichment analysis was conducted on genes associated with significantly causal metabolites in the validation dataset to assess biological pathway consistency across different RLS populations.

Validation Analysis 2: GSE271674 dataset processing: sample information was extracted from the series matrix file to ensure accurate group assignment and proper sample-to-condition mapping. Differential Expression Analysis: DESeq2 analysis was performed separately for MEIS1 overexpression versus control and MEIS1 knockout versus control comparisons. For each comparison, count matrices were filtered to remove low-expression genes (genes with total counts < 10 across all samples), and DESeq2 normalization was applied. Differential expression analysis employed the Wald test with FDR correction for multiple testing (Benjamini-Hochberg method).Results included log2 fold changes, raw p-values, and FDR-adjusted p-values for each gene. Corrected Log2 Fold Change Calculation: To assess the net regulatory effect of MEIS1 on target genes, corrected log2 fold changes were calculated by subtracting the knockout log2 fold change from the overexpression log2 fold change (corrected_log2FC = OE_log2FC - KO_log2FC). Statistical significance of corrected log2 fold changes was evaluated using Fisher's method to combine p-values from both comparisons, followed by FDR correction. This approach accounts for the bidirectional nature of MEIS1 manipulation and provides a comprehensive assessment of MEIS1's regulatory impact on target genes. Target Gene Expression Analysis: Potassium channel gene family members were specifically extracted from the differential expression results. For genes of interest (KCNH3, PDE3A), raw expression data were retrieved from the original count matrix, integrated with sample grouping information, and analyzed for expression patterns across experimental conditions.

Validation Analysis 3: Cis-MR based on a single gene region, was used to evaluate the link between the OpenGWAS eQTL datasets and the RLS datasets, further validating the involvement of potassium channels.

3   Results

3.1 Genetic Correlation

LDSC analysis showed: (1) the SNP-based heritability of RLS dataset 1 was estimated at $h^2 = 0.1097$ (SE = 0.0194). The mean $\chi2$ statistic was 1.0843, and the intercept was 0.9933 (SE = 0.0094), indicating minimal confounding from population structure or technical artifacts after genomic control (GC) correction; (2) RLS dataset 2 showed higher heritability: $h^2=0.2073$ (SE=0.0442). The mean $\chi2$ was 1.1305, with an intercept of 1.0323 (SE = 0.0105), suggesting a robust genetic signal; (3) the genetic correlation between the two RLS datasets was low and non-significant: rg = 0.0122, SE = 0.0572, Z = 0.2132, P = 0.8312, indicating genetic heterogeneity; (4) the genetic correlation between opioids use and RLS dataset 1 showed significant positive: rg=0.0983, SE=0.0467, Z=2.1040, P=0.0354, indicating some shared genetic architecture. To further understand the difference between the two RLS datasets, Manhattan plots were plotted (**Fig. 2**).

Fig. 2 Manhattan Plots of the two RLS datasets

3.2 Causal Effects (MR analysis)

The MR analysis using rs2618039 (mapping to KCND3 gene) after screening as the only instrumental variable with the Wald ratio method showed a potential protective effect of opioids use on RLS risk (OR=0.613, 95% CI: 0.359-1.046, P=0.072), which was a potential protective effect, not reaching conventional statistical significance. Reverse MR analysis (RLS as exposure and opioids use as outcome) showed a significant causal effect (OR=1.066, 95% CI: 1.011-1.124, P=0.018), indicating that RLS increased the risk of opioids use.

3.3 Mediation Analysis

Stage 1 (Opioids Use → 1402 CSF and Brain Metabolites): Using the Wald ratio method (single instrumental variable analysis), 51 significant associations between opioids use and CSF and brain metabolites (P<0.05) were retained as candidates after excluding 2 reverse causality relationships and 2 drug concentration-related exposures (**Fig. 3**A and C).

Stage 2 (1402 CSF and Brain Metabolites → RLS dataset1): MR analysis identified 44 significant causal relationships between CSF and brain metabolites and RLS dataset 1 using the IVW method (P<0.05) without reverse causality relationship, which as candidates were included in subsequent mediation analysis (**Fig. 3**B and D). To preserve more genetic signals, multiple testing correction was not performed on the candidate MR results.

Key Mediators and Temporal Effects: Bootstrap mediation analysis (10,000 iterations) identified four key CSF and brain mediators and the direct effect: cerebrospinal fluid cortisol (GCST90318234, a-effect β=-0.181, P=0.008; b-effect β=0.594, P=0.021; indirect effect=-0.108, mediation proportion=21.96%), urea (GCST90318260, a-effect β=-0.139, P=0.038; b-effect β=0.692, P=0.013; indirect effect=-0.096, mediation proportion=19.60%), fructose (GCST90318283, a-effect β=-0.124, P=0.005; b-effect β=-0.990, P=0.005; indirect effect=0.123, mediation proportion=-25.07%), and brain ceramides (GCST90318755, a-effect β=0.358,

P=0.029; b-effect β=0.221, P=0.019; indirect effect=0.079, mediation proportion=-16.12%); the direct effect=-0.488.

The idealized temporal mediation model suggested that short-term opioids use provided significant protective effects (OR=0.501, 95% CI: 0.273-0.918, P=0.025), however, the effect decreased (OR=0.751, 95% CI: 0.411-1.371, P=0.351) when the risk mediation effect (fructose depletion and ceramide accumulation) was activated and the protective mediation (cortisol and urea suppression) effect was ineffective (**Fig. 3**E).

Fig. 3 Mediation analysis and simulated temporal mediation model

Forest plots and volcano plots showing causal effects of opioids use on 51 candidate CSF and brain metabolites (A, C), and causal effects of 44 candidate CSFand brain metabolites on RLS (B, D). (E) By removing suspicious long-term risk mediators, the short-term efficacy of opioids use becomes significant.

3.4 Colocalization Analysis

Based on the colocalization analysis of 1402 CSF and brain metabolites and RLS dataset 1, a strong colocalization evidence was identified for SNP rs11045279 between CSF 4-acetamidophenylglucuronide levels (GCST90317906) and RLS dataset 1, which maps to the PDE3A gene region and involves reward mechanisms. The posterior probability of colocalization (PP.H4) reached 87.2%, exceeding the conventional threshold for robust genetic colocalization. Parameter sensitivity analysis across different prior combinations (p1/p2=1e-4 to 1e-6, p12=1e-5 to 1e-7) showed robust colocalization with H4 values consistently above 0.8 under mainstream recommended priors, confirming the stability of this finding.

3.5 Enrichment Analysis

To further explore the pathogenesis of RLS, GO and KEGG pathway enrichment analysis was conducted using 486 genes obtained from instrumental variable SNPs of significant Mendelian randomization results between CSF and brain metabolites and RLS dataset 1 (**Fig. 4**A-D).

The GO enrichment analysis from 486 input genes showed, 45 biological processes (BP), 23 cellular components (CC), and 16 molecular functions (MF) reached statistical significance (p.adjust<0.05). The analysis showed multiple potassium channel-related pathways were significantly enriched, including potassium channel complex (GO:0034705, CC, 14 genes, p.adjust=3.77e-05, fold enrichment=5.92), voltage-gated potassium channel complex (GO:0008076, CC, 13 genes, p.adjust=3.77e-05, fold enrichment=6.17) and potassium ion transmembrane transport (GO:0071805, BP, 18 genes, p.adjust=0.0032, fold enrichment=3.51), indicating that potassium ion channels play a crucial role. Synaptic function-related pathways were prominently represented, with postsynaptic density membrane (GO:0098839, CC, 12 genes, p.adjust=0.00254, fold enrichment=4.03), synapse assembly (GO:0007416, BP, 20 genes, p.adjust=0.00387, fold enrichment=3.09) and positive regulation of axonogenesis (GO:0050772, BP, 10 genes, p.adjust=0.00387, fold enrichment=5.7), supporting the involvement of synapse in RLS pathophysiology.

Fig. 4 GO and KEGG enrichment analysis (A-D from RLS dataset 1; E-H from RLS dataset 2)

Fig. 5 Comparison of enrichment analysis results (intersection part)

8 KEGG pathways reached statistical significance (p.adjust<0.05), with morphine addiction pathway showing the strongest enrichment (11 genes, p.adjust=0.00335, fold enrichment=4.98). Other significantly enriched pathways included axon guidance, GABAergic synapse, serotonergic synapse, and cholinergic synapse.

3.6 Validation Analyses

To preserve sufficient genetic signals, multiple testing correction was not performed on the MR analysis results. To control false positive rates and improve the reliability of the results, three different dimensions of validation analysis were conducted to support the involvement of potassium channels in the development of RLS.

Validation Analysis 1: I conducted MR analysis using 1402 cerebrospinal fluid and brain metabolites and the RLS dataset 2, which identified 59 metabolites with significant causal effects (P<0.05). Finally, 877 genes were obtained for enrichment

analysis after screening, and 133 GO enrichment analysis entries and 32 KEGG pathways with statistical significance were identified (**Fig. 4**E-H), then compared with the enrichment analysis results of the discovery stage, based on the intersection of the two significance results (p.adjust<0.05). Bivariate correlation analysis results based on fold enrichment showed consistency in synaptic function, potassium ion channel and membrane potential regulation, and cell connectivity (**Fig. 5**), supporting robust biological pathway convergence despite genetic heterogeneity.

Validation Analysis 2: Through differential expression analysis of genes in the GSE271674 dataset and extraction of genes of interest, the analysis results showed significant differential expression of key potassium channel-related genes under MEIS1 manipulation. For KCNH3 (potassium voltage-gated channel subfamily H member 3), MEIS1 activation resulted in significant upregulation (log2FC=2.20, P=2.04e-16), while MEIS1 knockout showed no significant change (log2FC=0.48, P=0.487). The corrected log2 fold change, accounting for bidirectional MEIS1 manipulation, was 1.72 (FDR-corrected P=4.39e-13), indicating robust MEIS1-mediated positive regulation of KCNH3. In addition, after knocking out the MEIS1 gene, the expression of KCNC1 gene showed a downward trend compared to the control group (log2FC=-0.34, P=1.17e-4).

For PDE3A (phosphodiesterase 3A), the gene mapped from the colocalization analysis result, MEIS1 activation led to significant downregulation (log2FC=-0.66, P=1.24e-9), while knockout showed no significant effect (log2FC=0.123, P=0.106). The corrected log2 fold change was -0.78 (FDR-corrected P=1.92e-7), demonstrating significant MEIS1-mediated negative regulation of PDE3A. The result indicates that MEIS1 overexpression reduces PDE3A expression.

Validation Analysis 3: After screening, 40 instrumental variable data were obtained from the eQTL dataset of 50 KCN-genes for cis-MR analysis to evaluate the impact of potassium channels related genes on RLS. For RLS dataset 1, the cis-MR analysis result showed that 2 candidate genes (KCNIP2 and KCNAB2) with potential roles but failed to correct for multiple tests. For RLS dataset 2, the cis-MR analysis result showed that 15 candidate genes with potential roles, of which 7 genes (KCNK13,

KCNAB1, KCNQ5, KCNJ15, KCNMA1, KCNN4 and KCNK6) passed multiple tests correction (**Fig. 6**).

Fig. 6 Cis-MR results between KCN-gene eQTLs and RLS dataset 2

Together, these findings supported that the pathogenesis of RLS involves potassium channels regulation, and may also be accompanied by synaptic function and addiction mechanism.

4 Discussion

4.1 Mediation Mendelian randomization and Simulated Temporal Mediation Model

This study provided genetic support, under MR assumptions, for a potential bidirectional relationship between opioids use and RLS. In the simulated temporal mediation model, the four mediators (CSF cortisol, urea, fructose, and brain ceramides), identified from mediation analysis then adding idealized time attributes, provides mechanistic insight into the temporal dynamics of opioids-RLS interactions.

According to Reeves et al. (2022)[23], opioid receptors can modulate various potassium channels through multiple signaling pathways. Regulation of voltage-gated potassium (Kv) channels plays a pivotal role in the analgesic, reward-related, addictive, and neuroplastic effects of opioids, exhibiting pronounced brain region- and cell type-specificity. In contrast, activation of G protein–gated inwardly rectifying potassium (GIRK) channels produces rapid and robust neuronal hyperpolarization.[23] It is biologically reasonable to improve symptoms of RLS by reducing excitability through cell membrane hyperpolarization The data analysis results of this study in multiple dimensions support the mechanism of RLS may involve potassium channels. Based on this evidence, the first assumption of the model was proposed: opioids can exert a constant direct protective effect through potassium channels activation (the rationality will be further demonstrated in the subsequent section).

Time-dependent mediating factors either enhance or counteract this effect at specific stages:

Short-term Protective Mechanisms:

- HPA axis suppression: Opioids reduce cerebrospinal fluid cortisol levels[24], thereby decreasing synaptic excitability[25,26] and may provide protective effects.

- Blood-brain barrier modulation: Although the precise mechanism requires further investigation, decreased cerebrospinal fluid urea levels may suggest altered blood-brain barrier permeability. An animal study suggested that the blood-brain barrier is involved in the formation of blood and CSF urea concentration gradients[27].

Long-term Risk Mechanisms:

- Metabolic dysregulation: Reduced cerebrospinal fluid fructose levels may impair dopamine-mediated reward mechanisms and exacerbate RLS symptoms, as fructose may stimulate dopamine secretion[28].

- Tolerance development: Opioids use can lead to the accumulation of brain ceramides and the development of tolerance[29]. Ceramides play a crucial role in normal and neurological function and disease processes by regulating synaptic tructure,

neurotransmitter transmission, and plasticity[30].

The temporal mediation model showed that opioids exerted significant short-term protective effects against RLS (OR=0.501, 95% CI: 0.273-0.918, P=0.025), under the condition KCND3-encoded voltage-gated potassium channels combined with protective mediating factors are effective. However, long-term effects involve risk mediating factors mediated by metabolic dysregulation (fructose depletion and ceramide accumulation), which mask this protective signal, resulting in marginally significant overall causal estimates (OR=0.613, 95% CI: 0.359-1.046, P=0.072), despite strong biological evidence for therapeutic efficacy[8–10].

4.2　Pathophysiological Mechanisms

Potassium channels and membrane potential: Potassium channels locate in cell membranes, and based on gene family, structure and functional characteristics, that are grouped into four families: *1*) calcium- and sodium-activated potassium channels (KCa/Na) (6/7 TMs); *2*) inwardly rectifying potassium channels (Kir) (2 TMs); *3*) two-pore-domain potassium channels (K2P) (4 TMs); and *4*) voltage-gated potassium channels (Kv) (6 TMs)[31]. Potassium channels play an important role in maintaining resting potential, repolarizing action potential, and regulating cellular excitability[32]. In neuronal cells, potassium channels maintain homeostasis and regulate neuronal firing properties and membrane potential[33], and participate in the regulation and plasticity of synaptic function[34]. Potassium channels are fundamental determinants of neuronal excitability through their control of resting membrane potential and firing threshold. Reduced potassium channel function shifts the resting potential toward depolarization, lowering the threshold for action potential initiation and converting neurons from Type II (high-threshold) to Type I (low-threshold) excitability patterns[35]. This dysfunction may create a cascade of membrane potential abnormalities: depolarized resting potential, prolonged repolarization time, enhanced neuronal excitability, and amplified synaptic signaling. The resulting membrane potential instability not only triggers

classic RLS symptoms through aberrant activation of low-threshold sensory channels and may also affects multiple physiological systems. Opioid receptors are known to modulate various potassium channels[23]. It is thus biologically plausible that opioids improve RLS by hyperpolarizing neurons via potassium channel activation.

This study proposes for the first time that RLS is associated with potassium channel regulation dysfunction. The identification of rs2618039 in the KCND3 gene as the primary instrumental variable for the main pharmacological effect of opioids use provides a genetic clue linking voltage-gated potassium channels to RLS pathophysiology. For RLS GWAS dataset 1, the functional enrichment analysis of 486 genes derived from 44 significant metabolite mediators also provides an important clue: the involvement of potassium channels. The validation analysis using an independent RLS GWAS dataset 2 provides robust support for this finding. Despite the low genetic correlation (rg = 0.0122, P = 0.8312) between the two RLS datasets, indicating genetic heterogeneity, the biological pathway analysis showed strong enrichment for potassium-channel complexes and related pathways, indicating a common central mechanism across RLS populations —— "Membrane Potential Polarization Disorder" hypothesis: regardless of upstream causes, aberrant polarization of neuronal membranes unifies RLS phenotypes. However, it is worth noting that the validation data has stronger heritability and more significant susceptibility genes, suggesting a more concentrated upstream etiology and leading to more significant results in the replication stage. This phenomenon likely reflects the inherent limitation of current RLS diagnostic criteria, which rely solely on symptom-based definitions without effective causal stratification. The symptom-based approach may inadvertently group together distinct RLS subtypes with different underlying causes, leading to diluted signals of genetic variation and difficulty to capture.

The result of validation analysis 2 indicates that activation of MEIS1 gene can cause upregulation of KCNH3 gene expression. Recent studies have shown that KCNH3 gene plays a crucial role in regulating the nighttime repetitive firing rate of the suprachiasmatic nucleus neurons and controlling their circadian rhythm. Therefore, knocking out the MEIS1 gene may lead to a decrease in the regulatory ability of

circadian rhythm mediated by the inability to activate the KCNH3 gene function. This dynamic regulatory pattern may further lead to an increase in false negative results, as it is impossible to distinguish the differential expression of KCNH3 gene between MEIS1 knockout and resting state. The cis-MR analysis based on the single gene eQTL datasets showed more significant causal relationships between several potassium channel-related genes and the RLS dataset 2, further strongly supporting the involvement of potassium channels and the guess of genetic variation signal dilution.

Dopaminergic system changes and addiction: Parkinson's disease is considered a neurodegenerative disorder related with declining dopamine levels[36]. Dopamine receptor agonists have therapeutic effects on both Parkinson's disease and RLS, leading to their association. However, there is no genetic evidence demonstrating a connection between these conditions[37]. Cerebrospinal fluid testing, neuroimaging and post-mortem studies in RLS patients consistently demonstrate dopaminergic system hyperactivity[3,4], and the latter two also demonstrate secondary dopamine receptor downregulation. Previous studies have shown that changes in excitability and dopamine secretion of dopaminergic neurons can be regulated by different types of potassium ion channels through membrane potential[38,39]. Overall, depolarization of membrane potential leads to an increase in firing frequency and dopamine secretion of dopaminergic neurons. On the contrary, activated dopaminergic neurons maintain homeostasis by compensatory increase in potassium channel currents[40,41], while increased dopamine may reduce presynaptic glutamate release through D2 receptor-mediated inhibition of the indirect pathway, thereby indirectly suppressing synaptic excitability via GABAergic interneuron activity in the striatum[42]. These pieces of evidence suggest that the brain in RLS may attempt to counteract excitability changes caused by membrane potential dysfunction by compensatory secretion of dopamine. However, Chronic dopamine stimulation may induce D2 receptor downregulation and synaptic plasticity changes, contributing to addiction vulnerability[42], and may create a sustained state of "dopamine hyperactivity-hypoallergenic".

KEGG enrichment analysis showed involvement in the mechanism of morphine addiction and was replicated in validation analysis 1. Interestingly, the probability of

developing restless leg syndrome during opioid withdrawal is higher than during alcohol withdrawal[43,44], indicating that opioid may also mediate the occurrence of restless leg syndrome through morphine addiction. The addiction mechanisms may be both a result and a cause for development of RLS. This explains the phenomenon of symptom relief-aggravation that occurs with long-term use of dopamine agonists[2].

Iron-Membrane Potential Interdependence: Iron deficiency plays an important role in the occurrence and development of RLS. Although iron supplementation is preferred over other treatment methods, in RLS patients with concomitant iron deficiency. However, Brain iron deficiency has been proven to occur even if peripheral iron is normal[45], indicating the presence of iron transport disorders. Animal models show that iron deficiency increases acute and chronic pain responses in mice and may cause the increased pain sensitivity[46,47]. Opioid receptor knockout successfully replicates RLS symptoms in animal models, while simultaneously inducing iron deficiency and anemia[7]. The current theory cannot provide further explanations for these phenomena.

The hypothesis of this study provides a mechanistic explanation for the well-established association between iron deficiency and RLS that has puzzled researchers for decades. Previous studies have shown that membrane potential (or resting potential) has a significant impact on the transport and absorption of iron ions, and its fluctuations can regulate the transport and absorption of iron ions by changing the proton gradient and transmembrane electrochemical environment The influence of iron ions on membrane potential is relatively complex, however, due to the fact that iron ions are mainly transported in the form of Fe^{2+}, and many iron transport proteins such as DMT1 and ZIP family members rely on H^+ gradients during transport, the transport of iron ions indirectly affects membrane potential[48]. This bidirectional relationship may create a pathological feedback loop: iron deficiency $\rightarrow$ membrane depolarization $\rightarrow$ impaired iron transport $\rightarrow$ worsening brain iron deficiency, which explains the mechanism of the effectiveness of iron supplementation in treating restless leg syndrome, as well as the reason for its ineffectiveness[45] if it is due to depolarization driven by membrane

potential due to other reasons. In addition, iron transport disorders in the intestine may also lead to iron absorption disorders and exacerbate systemic iron deficiency.

Periodic Limb Movement Disorder and neural electrophysiology: At the genetic, epidemiological, electrophysiological, and pharmacological response levels, RLS and periodic limb movement disorder (PLMD) demonstrate remarkable similarities[49–51]. The electrophysiological studies showed that the depolarization current of peripheral motor nerve axons in restless leg syndrome increases, reduces the threshold for action potential release, promotes spontaneous discharge, and has stronger adaptability to hyperpolarization[52]. And there are similar manifestations in the spinal cord and brain, both with increased excitability[53,54]. The theory of this study unifies these two conditions, proposing that they represent different manifestations of membrane potential abnormalities in the nervous system: sensory symptoms and motor symptoms. RLS may be mapped to increased Type I neuronal excitability (sensory, continuous firing), while PLMD corresponds to increased Type II excitability (motor, burst firing).

Multi-system Involvement: Mice knocked out for BTBD9 showed motor restlessness, sensory alterations, decreased sleep, and altered serum iron levels, accompanied by cerebellar neuronal resting potential depolarization[55]. In mutant mice for MEIS1, hyperactivity was observed with a RLS-like circadian trend, associated with sensory alteration of functions modulated by dopaminergic networks, accompanied by increased risk of malignant arrhythmias[56]. The proportion of RLS is significantly increased in dialysis patients, which may be related to depolarization of membrane potential caused by hyperkalemia[57] and the effects of toxins on Na+/K+-ATPase. RLS and PLMD can also be attributed to sleep apnea syndrome, which may be membrane potential abnormalities caused by hypoxia-induced Na+/K+-ATPase inhibition. In summary, this hypothesis based on the cell membrane potential as the hub, can be used to explain the etiological heterogeneity of RLS and speculate that there may be manifestations of other system involvement, among which gastrointestinal and cardiac manifestations are most worthy of attention. Studies have shown that patients with RLS have a higher proportion of irritable bowel syndrome[58], which may aggravate iron

absorption disorders further leading to iron deficiency and anemia, given that iron ions in the intestine may also experience transmembrane transport disorders. In terms of cardiac electrophysiology, studies have shown that the fQRS-T angle of RLS patients is significantly widened, suggesting cardiac repolarization abnormalities[59]. Therefore, the risk of malignant arrhythmias in patients with RLS deserves attention. There are also reports that RLS patients have abnormal manifestations of the autonomic nervous system[58].

Genetic Susceptibility: Cerebrospinal fluid analysis and autopsy findings in RLS patients show deficiencies in endogenous opioid. The LDSC analysis supported genetic correlation between the two conditions, while reverse MR analysis indicated that RLS was a risk factor for opioids use. These findings suggested that the opioids use risk in RLS patients may be driven by genetic susceptibility. In other words, deficiency in endogenous opioid may predispose individuals to dependency, which can be either physiological or pathological. Physiological dependency can be viewed as a form of drug replacement therapy with sustained and stable therapeutic effects. This provides theoretical support for the sustained and stable therapeutic effects of opioid drugs observed in long-term follow-up studies[9,10]. However, the mechanisms underlying membrane potential abnormalities caused by secondary RLS may be more complex, potentially leading to the development of pathological dependency and addiction due to continuous dose escalation when opioids fail to address the underlying problem. This underscored the critical importance of effective assessment and optimal dose management in opioids use among patients with RLS.

Hypothesis-Based Definition: RLS is not a disease per se, but rather a description of clinical manifestations. In fact, this may be a multi-system membrane potential polarization disorder caused by various etiologies. In the central nervous system, neurons and synapses occur hyperexcitability, activating dopaminergic neuron for negative feedback regulation, which leads to increased dopamine secretion causes reinforcement of addiction mechanisms. Although low-threshold ion channels throughout the body are affected, the human body's perceptual ability for low-threshold ion channels in sensory nervous system may be superior to other locations, leading to

the high proportion of RLS development. Motor symptoms manifest as PLMD, while peripheral symptoms present as gastrointestinal dysfunction, iron absorption and transport disorders, cardiac electrophysiological abnormalities, and autonomic nervous system dysfunction. Considering the compensatory mechanisms of the dopaminergic system in the brain, it can be further classified into an asymptomatic compensated phase and a symptomatic decompensated phase. As is well known, sensory symptoms include not only discomfort but also an irresistible urge to move the lower limbs, complete relief after activity, and circadian rhythm changes. The complete relief after activity may be due to repolarization and hyperpolarization that occur after action potentials, while simultaneously, symptom relief reduces the dopaminergic burden of abnormally activated reward mechanisms, or symptom relief-dopamine secretion coupling phenomena occur. The strong desire for activity may be driven by addiction mechanism. The circadian rhythm changes may be due to increased neurons and synapses excitability leading to loss of control over circadian rhythm and light regulation of synapses, resulting in failure of nighttime synaptic excitability to decrease on schedule. In addition, the abnormal baseline of synaptic plasticity and neurotransmitters in long-term pathological states makes understanding this process more complex.

Limitations: Several caveats merit mention. First, The GWAS data were predominantly of European ancestry, limiting generalizability; effect sizes and LD may differ in other populations. Second, the temporal mediation model is conceptual and relies on theoretical assumptions, since cross-sectional GWAS cannot capture dynamic changes; longitudinal metabolomic/clinical data would be needed to validate the time course. Third, I used a single SNP (rs2618039) as the opioid instrument (though it is strong, $F \approx 30.6$), and a relaxed significance threshold for metabolites. While this risks false positives, I mitigated it by rigorous confounder filtering and multi-layer validation. The metabolite-RLS MR results were not Bonferroni-corrected (which could inflate type I error), but the comprehensive strategy – liberal initial screening followed by functional enrichment and multiple validation steps – helps filter out spurious findings. Fourth, the opioid-use phenotype encompassed all prescription opioids (ATC N02A)

without detail on dose, duration or specific drug, potentially diluting drug-specific genetic effects. Fifth, "multi-system membrane potential polarization disorder" remains a hypothesis; we lack direct experimental validation. However, its explanatory power is notable, coherently unifying the various unexplainable phenomena of RLS. The convergent evidence from genetic correlation, bidirectional MR, mediation analysis, enrichment and multiple validation streams lends credibility to this model even absent bench experiments.

5   Conclusion

This study provides the genetic support for a bidirectional causal relationship between opioid use and RLS and identifies membrane potential polarization disorder—driven by potassium channel regulation dysfunction—as the potential core pathophysiological mechanism. By integrating genetic, metabolic, and functional evidence, including temporal mediation Mendelian randomization, four key cerebrospinal fluid and brain metabolites (cortisol, urea, fructose, ceramides) were found that modulate the time-dependent therapeutic effects of opioids, delineating short-term protective and long-term risk pathways. Importantly, functional enrichment and multi-layer validation converge on potassium channel regulation dysfunction, as the driver of neuronal hyperexcitability, secondary dopaminergic adaptations, and multi-system manifestations, that shows strong explanatory power in biology. Current symptom-based RLS definitions could dilute GWAS signals; etiology-based stratification could concentrate heritability, uncover robust susceptibility loci, and accelerate causal pathway discovery. These findings may help to reconceptualize RLS as a mechanism-based, multi-system disorder and provide a framework for biomarker-guided diagnosis, precision patient stratification, targeted drug development, and systematic surveillance for cardiac, gastrointestinal, and autonomic comorbidities. Future work should validate these mechanisms in longitudinal and functional studies, incorporating etiological subtyping to refine genetic architecture and translate mechanistic insights into clinical benefit.

References

1. Song, P., Wu, J., Cao, J., Sun, W., Li, X., Zhou, T., Shen, Y., Tan, X., Ye, X., Yuan, C., Zhu, Y., Rudan, I., & Global Health Epidemiology Research Group (GHERG). (2024). The global and regional prevalence of restless legs syndrome among adults: A systematic review and modelling analysis. *Journal of Global Health*, *14*. https://doi.org/10.7189/jogh.14.04113

2. Khachatryan, S. G., Ferri, R., Fulda, S., Garcia-Borreguero, D., Manconi, M., Muntean, M., & Stefani, A. (2022). Restless legs syndrome: Over 50 years of European contribution. *Journal of Sleep Research*, *31*(4). https://doi.org/10.1111/jsr.13632

3. Allen, R. P., Connor, J. R., Hyland, K., & Earley, C. J. (2009). Abnormally increased CSF 3-ortho-methyldopa (3-OMD) in untreated restless legs syndrome (RLS) patients indicates more severe disease and possibly abnormally increased dopamine synthesis. *Sleep Medicine*, *10*(1), 123–128. https://doi.org/10.1016/j.sleep.2007.11.012

4. Walters, A. S., Li, Y., Koo, B. B., Ondo, W. G., Weinstock, L. B., Champion, D., Afrin, L. B., Karroum, E. G., Bagai, K., & Spruyt, K. (2024). Review of the role of the endogenous opioid and melanocortin systems in the restless legs syndrome. *Brain*, *147*(1), 26–38. https://doi.org/10.1093/brain/awad283

5. Koo, B. B., Abdelfattah, A., Eysa, A., & Lu, L. (2024). The melanocortin and endorphin neuropeptides in patients with restless legs syndrome. *Annals of Neurology*, *95*(4), 688–699. https://doi.org/10.1002/ana.26876

6. Walters, A. S., Ondo, W. G., Zhu, W., & Le, W. (2009). Does the endogenous opiate system play a role in the restless legs syndrome?: A pilot post-mortem study. *Journal of the Neurological Sciences*, *279*(1–2), 62–65. https://doi.org/10.1016/j.jns.2008.12.022

7. Lyu, S., DeAndrade, M. P., Mueller, S., Oksche, A., Walters, A. S., & Li, Y. (2019). Hyperactivity, dopaminergic abnormalities, iron deficiency and anemia in an in vivo opioid receptors knockout mouse: Implications for the restless legs syndrome. *Behavioural Brain Research*, *374*, 112123. https://doi.org/10.1016/j.bbr.2019.112123

8. Trenkwalder, C., Beneš, H., Grote, L., García-Borreguero, D., Högl, B., Hopp, M., Bosse, B., Oksche, A., Reimer, K., Winkelmann, J., Allen, R. P., & Kohnen, R. (2013). Prolonged release oxycodone–naloxone for treatment of severe restless legs syndrome after failure of previous treatment: A double-blind, randomised, placebo-controlled trial with an open-label extension. *Lancet Neurology*, *12*(12), 1141–1150. https://doi.org/10.1016/s1474-4422(13)70239-4

9. Silver, N., Allen, R. P., Senerth, J., & Earley, C. J. (2011). A 10-year, longitudinal assessment of dopamine agonists and methadone in the treatment of restless legs syndrome. *Sleep Medicine*, *12*(5), 440–444. https://doi.org/10.1016/j.sleep.2010.11.002

10. Winkelman, J. W., Wipper, B., & Zackon, J. (2023). Long-term safety, dose stability, and efficacy of opioids for patients with restless legs syndrome in the national RLS opioid registry. *Neurology*, *100*(14). https://doi.org/10.1212/wnl.0000000000206855

11. Richmond, R. C., & Davey Smith, G. (2022). Mendelian randomization: Concepts and scope. *Cold Spring Harbor Perspectives in Medicine*, *12*(1), a040501. https://doi.org/10.1101/cshperspect.a040501

12. Wu, Y., Byrne, E. M., Zheng, Z., Kemper, K. E., Yengo, L., Mallett, A. J., Yang, J., Visscher, P. M., & Wray, N. R. (2019). Genome-wide association study of medication-use and associated disease in the UK biobank. *Nature Communications*, *10*(1). https://doi.org/10.1038/s41467-019-09572-5

13. Akçimen, F., Chia, R., Saez-Atienzar, S., Ruffo, P., Rasheed, M., Ross, J. P., Liao, C., Ray, A., Dion, P. A., Scholz, S. W., Rouleau, G. A., & Traynor, B. J. (2024). Genomic analysis identifies risk factors in restless legs syndrome. *Annals of Neurology*, *96*(5), 994–1005. https://doi.org/10.1002/ana.27040

14. Schormair, B., Zhao, C., Bell, S., Didriksen, M., Nawaz, M. S., Schandra, N., Stefani, A., Högl, B., Dauvilliers, Y., Bachmann, C. G., Kemlink, D., Sonka, K., Paulus, W., Trenkwalder, C., Oertel, W. H., Hornyak, M., Teder-Laving, M., Metspalu, A., Hadjigeorgiou, G. M., … Winkelmann, J. (2024). Genome-wide meta-analyses of restless legs syndrome yield insights into genetic architecture, disease biology and risk prediction. *Nature Genetics*, *56*(6), 1090–1099. https://doi.org/10.1038/s41588-024-01763-1

15. Wang, C., Yang, C., Western, D., Ali, M., Wang, Y., Phuah, C.-L., Budde, J., Wang, L., Gorijala, P., Timsina, J., Ruiz, A., Pastor, P., Fernandez, M. V., Dominantly Inherited Alzheimer Network (DIAN), Perrin, R., The Alzheimer's Disease Neuroimaging Initiative (ADNI), Panyard, D. J., Engelman, C. D., Deming, Y., … Cruchaga, C. (2024). Genetic architecture of cerebrospinal fluid and brain metabolite levels and the genetic colocalization of metabolites with human traits. *Nature Genetics*, *56*(12), 2685–2695. https://doi.org/10.1038/s41588-024-01973-7

16. Kittke, V., Zhao, C., Lam, D. D., Harrer, P., Krezel, W., Schormair, B., Oexle, K., & Winkelmann, J. (2024). RLS-associated MEIS transcription factors control distinct processes in human neural stem cells. *Scientific Reports*, *14*(1), 28986. https://doi.org/10.1038/s41598-024-80266-9

17. Gkatzionis, A., Burgess, S., & Newcombe, P. J. (2023). Statistical methods for *cis* -mendelian randomization with two-sample summary-level data. *Genetic Epidemiology*, *47*(1), 3–25. https://doi.org/10.1002/gepi.22506

18. Schizophrenia Working Group of the Psychiatric Genomics Consortium, Bulik-Sullivan, B. K., Loh, P.-R., Finucane, H. K., Ripke, S., Yang, J., Patterson, N., Daly, M. J., Price, A. L., & Neale, B. M. (2015). LD score regression distinguishes confounding from polygenicity in genome-wide association studies. *Nature Genetics*, *47*(3), 291–295. https://doi.org/10.1038/ng.3211

19. Verbanck, M., Chen, C.-Y., Neale, B., & Do, R. (2018). Detection of widespread horizontal pleiotropy in causal relationships inferred from mendelian randomization between complex traits and diseases. *Nature Genetics*, *50*(5), 693–698. https://doi.org/10.1038/s41588-018-0099-7

20. Cohen, J. F., Chalumeau, M., Cohen, R., Korevaar, D. A., Khoshnood, B., & Bossuyt, P. M. M. (2015). Cochran's Q test was useful to assess heterogeneity in likelihood ratios in studies of diagnostic accuracy. *Journal of Clinical Epidemiology*, *68*(3), 299–306. https://doi.org/10.1016/j.jclinepi.2014.09.005

21. Bowden, J., Davey Smith, G., & Burgess, S. (2015). Mendelian randomization with invalid instruments: Effect estimation and bias detection through egger regression. *International Journal of Epidemiology*, *44*(2), 512–525. https://doi.org/10.1093/ije/dyv080

22. Zuber, V., Grinberg, N. F., Gill, D., Manipur, I., Slob, E. A. W., Patel, A., Wallace, C., & Burgess, S. (2022). Combining evidence from mendelian randomization and colocalization: Review and comparison of approaches. *American Journal of Human Genetics*, *109*(5), 767–782. https://doi.org/10.1016/j.ajhg.2022.04.001

23. Reeves, K. C., Shah, N., Muñoz, B., & Atwood, B. K. (2022). Opioid receptor-mediated regulation of neurotransmission in the brain. *Frontiers in Molecular Neuroscience*, *15*, 919773. https://doi.org/10.3389/fnmol.2022.919773

24. De Vries, F., Bruin, M., Lobatto, D. J., Dekkers, O. M., Schoones, J. W., Van Furth, W. R., Pereira, A. M., Karavitaki, N., Biermasz, N. R., & Zamanipoor Najafabadi, A. H. (2020). Opioids and their endocrine effects: A systematic review and meta-analysis. *Journal of Clinical Endocrinology and Metabolism*, *105*(4), 1020–1029. https://doi.org/10.1210/clinem/dgz022

25. Wamsteeker Cusulin, J. I., & Bains, J. S. (2015). Embedded synaptic feedback in the neuroendocrine stress axis. *Journal of Neuroendocrinology*, *27*(6), 481–486. https://doi.org/10.1111/jne.12260

26. Tse, Y. C., Bagot, R. C., & Wong, T. P. (2012). Dynamic regulation of NMDAR function in the adult brain by the stress hormone corticosterone. *Frontiers in Cellular Neuroscience*, *6*. https://doi.org/10.3389/fncel.2012.00009

27. Parandoosh, Z., & Johanson, C. E. (1982). Ontogeny of blood-brain barrier permeability to, and cerebrospinal fluid sink action on, [14C]urea. *American Journal of Physiology-Regulatory, Integrative and Comparative Physiology*, *243*(3), R400–R407. https://doi.org/10.1152/ajpregu.1982.243.3.r400

28. Flores Monar, G. V., Sanchez Cruz, C., & Calderon Martinez, E. (2025). Mindful eating: A deep insight into fructose metabolism and its effects on appetite regulation and brain function. *Journal of Nutrition and Metabolism*, *2025*(1). https://doi.org/10.1155/jnme/5571686

29. Bryant, L., Doyle, T., Chen, Z., Cuzzocrea, S., Masini, E., Vinci, M. C., Esposito, E., Mazzon, E., Petrusca, D. N., Petrache, I., & Salvemini, D. (2009). Spinal ceramide and neuronal apoptosis in morphine antinociceptive tolerance. *Neuroscience Letters*, *463*(1), 49–53. https://doi.org/10.1016/j.neulet.2009.07.051

30. Brodowicz, J., Przegaliński, E., Müller, C. P., & Filip, M. (2018). Ceramide and its related neurochemical networks as targets for some brain disorder therapies. *Neurotoxicity Research*, *33*(2), 474–484. https://doi.org/10.1007/s12640-017-9798-6

31. Cosme, D., Estevinho, M. M., Rieder, F., & Magro, F. (2021). Potassium channels in intestinal epithelial cells and their pharmacological modulation: A systematic review. *American Journal of Physiology Cell Physiology*, *320*(4), C520–C546. https://doi.org/10.1152/ajpcell.00393.2020

32. Alexander, S. P. H., Mathie, A., Peters, J. A., Veale, E. L., Striessnig, J., Kelly, E., Armstrong, J. F., Faccenda, E., Harding, S. D., Pawson, A. J., Sharman, J. L., Southan, C., Davies, J. A., & CGTP Collaborators. (2019). THE CONCISE GUIDE TO PHARMACOLOGY 2019/20: Ion channels. *British Journal of Pharmacology*, *176*(S1). https://doi.org/10.1111/bph.14749

33. Alam, K. A., Svalastoga, P., Martinez, A., Glennon, J. C., & Haavik, J. (2023). Potassium channels in behavioral brain disorders. Molecular mechanisms and therapeutic potential: A narrative review. *Neuroscience & Biobehavioral Reviews*, *152*, 105301. https://doi.org/10.1016/j.neubiorev.2023.105301

34. Luo, H., Marron Fernandez De Velasco, E., & Wickman, K. (2022). Neuronal G protein-gated K$^+$ channels. *American Journal of Physiology Cell Physiology*, *323*(2), C439–C460. https://doi.org/10.1152/ajpcell.00102.2022

35. Drion, G., O'Leary, T., & Marder, E. (2015). Ion channel degeneracy enables robust and tunable neuronal firing rates. *Proceedings of the National Academy of Sciences*, *112*(38). https://doi.org/10.1073/pnas.1516400112

36. Tanner, C. M., & Ostrem, J. L. (2024). Parkinson's disease. *New England Journal of Medicine*, *391*(5), 442–452. https://doi.org/10.1056/nejmra2401857

37. Estiar, M. A., Senkevich, K., Yu, E., Varghaei, P., Krohn, L., Bandres-Ciga, S., Noyce, A. J., Rouleau, G. A., & Gan-Or, Z. (2021). Lack of causal effects or genetic correlation between restless legs syndrome and parkinson's disease. *Movement Disorders*, *36*(8), 1967–1972. https://doi.org/10.1002/mds.28640

38. Iyer, R., Ungless, M. A., & Faisal, A. A. (2017). Calcium-activated SK channels control firing regularity by modulating sodium channel availability in midbrain dopamine neurons. *Scientific Reports*, *7*(1), 5248. https://doi.org/10.1038/s41598-017-05578-5

39. Canavier, C. C., & Landry, R. S. (2006). An increase in AMPA and a decrease in SK conductance increase burst firing by different mechanisms in a model of a dopamine neuron in vivo. *Journal of Neurophysiology*, *96*(5), 2549–2563. https://doi.org/10.1152/jn.00704.2006

40. Friedman, A. K., Walsh, J. J., Juarez, B., Ku, S. M., Chaudhury, D., Wang, J., Li, X., Dietz, D. M., Pan, N., Vialou, V. F., Neve, R. L., Yue, Z., & Han, M.-H. (2014). Enhancing depression mechanisms in midbrain dopamine neurons achieves homeostatic resilience. *Science*, *344*(6181), 313–319. https://doi.org/10.1126/science.1249240

41. Liu, E., Pang, K., Liu, M., Tan, X., Hang, Z., Mu, S., Han, W., Yue, Q., Comai, S., & Sun, J. (2023). Activation of Kv7 channels normalizes hyperactivity of the VTA-NAcLat circuit and attenuates methamphetamine-induced conditioned place preference and sensitization in mice. *Molecular Psychiatry*, *28*(12), 5183–5194. https://doi.org/10.1038/s41380-023-02218-5

42. Wise, R. A., & Jordan, C. J. (2021). Dopamine, behavior, and addiction. *Journal of Biomedical Science*, *28*(1). https://doi.org/10.1186/s12929-021-00779-7

43. McCarter, S. J., Labott, J. R., Mazumder, M. K., Gebhard, J., Cunningham, J. L., Loukianova, L. L., Gilliam, W. P., & Lipford, M. C. (2023). Emergence of restless legs syndrome during opioid discontinuation. *Journal of Clinical Sleep Medicine*, *19*(4), 741–748. https://doi.org/10.5664/jcsm.10436

44. Mackie, S. E., McHugh, R. K., McDermott, K., Griffin, M. L., Winkelman, J. W., & Weiss, R. D. (2017). Prevalence of restless legs syndrome during detoxification from alcohol and opioids. *Journal of Substance Abuse Treatment*, *73*, 35–39. https://doi.org/10.1016/j.jsat.2016.10.001

45. Connor, J. R., Patton, S. M., Oexle, K., & Allen, R. P. (2017). Iron and restless legs syndrome: Treatment, genetics and pathophysiology. *Sleep Medicine*, *31*, 61–70. https://doi.org/10.1016/j.sleep.2016.07.028

46. Dowling, P., Klinker, F., Amaya, F., Paulus, W., & Liebetanz, D. (2009). Iron-deficiency sensitizes mice to acute pain stimuli and formalin-induced nociception ,. *Journal of Nutrition*, *139*(11), 2087–2092. https://doi.org/10.3945/jn.109.112557

47. Yoo, J. J., Hayes, M., Serafin, E. K., & Baccei, M. L. (2023). Early-life iron deficiency persistently alters nociception in developing mice. *Journal of Pain*, *24*(8), 1321–1336. https://doi.org/10.1016/j.jpain.2023.03.012

48. Pasquadibisceglie, A., Bonaccorsi Di Patti, M. C., Musci, G., & Polticelli, F. (2023). Membrane transporters involved in iron trafficking: Physiological and pathological aspects. *Biomolecules*, *13*(8), 1172. https://doi.org/10.3390/biom13081172

49. Riccardi, S., Ferri, R., Garbazza, C., Miano, S., & Manconi, M. (2023). Pharmacological responsiveness of periodic limb movements in patients with restless legs syndrome: A systematic review and meta-analysis. *Journal of Clinical Sleep Medicine*, *19*(4), 811–822. https://doi.org/10.5664/jcsm.10440

50. Edelson, J. L., Schneider, L. D., Amar, D., Brink-Kjaer, A., Cederberg, K. L., Kutalik, Z., Hagen, E. W., Peppard, P. E., Tempaku, P. F., Tufik, S., Evans, D. S., Stone, K., Tranah, G., Cade, B., Redline, S., Haba-Rubio, J., Heinzer, R., Marques-Vidal, P., Vollenweider, P., … Mignot, E. (2023). The genetic etiology of periodic limb movement in sleep. *Sleep*, *46*(4). https://doi.org/10.1093/sleep/zsac121

51. Van Der Veen, S., Caviness, J. N., Dreissen, Y. E. M., Ganos, C., Ibrahim, A., Koelman, J. H. T. M., Stefani, A., & Tijssen, M. A. J. (2022). Myoclonus and other jerky movement disorders. *Clinical Neurophysiology Practice*, *7*, 285–316. https://doi.org/10.1016/j.cnp.2022.09.003

52. Czesnik, D., Howells, J., Bartl, M., Veiz, E., Ketzler, R., Kemmet, O., Walters, A. S., Trenkwalder, C., Burke, D., & Paulus, W. (2019). I_h contributes to increased motoneuron excitability in restless legs syndrome. *The Journal of Physiology*, *597*(2), 599–609. https://doi.org/10.1113/jp275341

53. Dafkin, C., McKinon, W., & Kerr, S. (2019). Restless legs syndrome: Clinical changes in nervous system excitability at the spinal cord level. *Sleep Medicine Reviews*, *47*, 9–17. https://doi.org/10.1016/j.smrv.2019.05.005

54. Kim, T.-J., Cha, K. S., Lee, S., Yang, T.-W., Kim, K. T., Park, B.-S., Jun, J.-S., Lim, J.-A., Byun, J.-I., Sunwoo, J.-S., Shin, J.-W., Kim, K. H., Lee, S. K., & Jung, K.-Y. (2020). Brain regions associated with periodic leg movements during sleep in restless legs syndrome. *Scientific Reports*, *10*(1). https://doi.org/10.1038/s41598-020-58365-0

55. Lyu, S., Xing, H., DeAndrade, M. P., Perez, P. D., Yokoi, F., Febo, M., Walters, A. S., & Li, Y. (2020). The role of BTBD9 in the cerebellum, sleep-like behaviors and the restless legs syndrome. *Neuroscience*, *440*, 85–96. https://doi.org/10.1016/j.neuroscience.2020.05.021

56. Bouilloux, F., Thireau, J., Ventéo, S., Farah, C., Karam, S., Dauvilliers, Y., Valmier, J., Copeland, N. G., Jenkins, N. A., Richard, S., & Marmigère, F. (2016). Loss of the transcription factor Meis1 prevents sympathetic neurons target-field innervation and increases susceptibility to sudden cardiac death. *Elife*, *5*. https://doi.org/10.7554/elife.11627

57. Weiss, J. N., Qu, Z., & Shivkumar, K. (2017). Electrophysiology of hypokalemia and hyperkalemia. *Circulation: Arrhythmia and Electrophysiology*, *10*(3). https://doi.org/10.1161/circep.116.004667

58. Acar, B., Acar, M., Acar, T., Varım, C., Alagöz, A., Demiryürek, E., Doğan Güngen, B., & Güzey Aras, Y. (2018). Patients with primary restless legs syndrome have   higher prevalence of autonomic dysfunction and irritable   bowel syndrome. *Singapore Medical Journal*, *59*(10), 539–544. https://doi.org/10.11622/smedj.2018010

59. Department of Cardiology, Adiyaman Training and Research Hospital, Adiyaman, Turkey, Abus, S., Kapici, Y., Department of Psychiatry, Kahta State Hospital, Adiyaman, Turkey, Ayhan, S., Department of Cardiology, Adiyaman Training and Research Hospital, Adiyaman, Turkey, Arik, A., & Department of Neurology, Adiyaman Training and Research Hospital, Adiyaman, Turkey.

(2023). Elevated cardiovascular disease risk in patients with restless legs syndrome. *Alpha Psychiatry*, *24*(3), 95–99. https://doi.org/10.5152/alphapsychiatry.2023.221043